CLL: Clinical
Presentation during EHA2023: All Oral presentations will be presented between Friday, June 9, and Sunday, June 11, and will be accessible for on-demand viewing from Monday, June 19 until Monday, August 14, 2023, on the Congress platform.
Abstract titles and summaries were obtained from the EHA website http://www.ehaweb.org, abstracts were translated, edited, and summarized in German.
- VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
- GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
- EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
- TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
- OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY
- IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
- FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)